New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers

Oncologist

Volumn 9, Issue 3, 2004, Pages 282-294

  Diaz Rubio, Eduardo ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Chemotherapy; Colorectal cancer; Gastric cancer; Gastrointestinal malignancy; Pancreatic cancer

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANCER VACCINE; CANERTINIB; CAPECITABINE; CETUXIMAB; CISPLATIN; CYANOCOBALAMIN; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FLAVOPIRIDOL; FLUOROURACIL; FOLIC ACID; FOLINIC ACID; GASTRIMMUNE; GASTRIN 17 DIPHTHERIA TOXOID; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; OXALIPLATIN; PEMETREXED; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB;

ALOPECIA; ANEMIA; ANIMAL MODEL; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUING EDUCATION; CYANOCOBALAMIN DEFICIENCY; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FOLIC ACID DEFICIENCY; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; MOUSE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NONHUMAN; ONCOLOGY; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STOMACH CANCER; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; COLORECTAL NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PANCREATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 2942696037     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-3-282     Document Type: Review

References (116)

1. Ries LAG, Eisner MP, Kosary CL et al., eds. SEER Cancer Statistics Review, 1973-1999. National Cancer Institute. Bethesda. http://seer.cancer.gov/csr/1973_1999/, 2002.
2. Edwards BK, Howe HL, Ries LA et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002;94:2766-2792.
3. Ghaneh P, Kawesha A, Evans JD et al. Molecular prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Surg 2002;9:1-11.
4. Greenlee RT, Murray T, Bolden S et al. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
5. Evans DB, Abbruzzese JL, Rich TZ. Cancer of the pancreas. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer, Principles and Practice of Oncology, Fifth Edition. Philadelphia: J.B. Lippincott Co., 1997:1054-1087.
6. Franceschi S, Levi F, La Vecchia C. Epidemiology of gastric cancer in Europe. Eur J Cancer Prev 1994;3(suppl 2):5-10.
7. Correa P. The epidemiology of gastric cancer. World J Surg 1991;15:228-234.
8. Sepulveda AR, Graham DY. Role of Helicobacter pylori in gastric carcinogenesis. Gastroenterol Clin North Am 2002;31:517-535.
9. Zhang L, Blot WJ, You WC et al. Serum micronutrients in relation to pre-cancerous gastric lesions. Int J Cancer 1994;56:650-654.
10. Buiatti E, Palli D, Decarli A et al. A case-control study of gastric cancer and diet in Italy: II. Association with nutrients. Int J Cancer 1990;45:896-901.
11. Hill MJ, Morson BC, Bussey HJ. Aetiology of adenomacarcinoma sequence in large bowel. Lancet 1978;1:245-247.
12. Rose DP, Boyar AP, Wynder EL. International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon, and per capita food consumption. Cancer 1986;58:2363-2371.
13. Alberts DS. Reducing the risk of colorectal cancer by intervening in the process of carcinogenesis: a status report. Cancer J 2002;8:208-221.
14. Bodmer WF, Bailey CJ, Bodmer J et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 1987;328:614-616.
15. Solomon E, Voss R, Hall V et al. Chromosome 5 allele loss in human colorectal carcinomas. Nature 1987;328:616-619.
16. Nishisho I, Nakamura Y, Miyoshi Y et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991;253:665-669.
17. Burris HA 3rd, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413.
18. Hansen R, Quebbeman E, Ritch P et al. Continuous 5-fluorouracil (5FU) infusion in carcinoma of the pancreas: a phase II study. Am J Med Sci 1988;295:91-93.
19. DeCaprio JA, Mayer RJ, Gonin R et al. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol 1991;9:2128-2133.
20. MacDonald JS, Schein PS, Woolley PV et al. 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 1980;93:533-536.
21. Cullinan SA, Moertel CG, Fleming TR et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 1985;253:2061-2067.
22. Vanhoefer U, Rougier P, Wilke H et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000;18:2648-2657.
23. Waters JS, Norman A, Cunningham D et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 1999;80:269-272.
24. Bleiberg H. CPT-11 in gastrointestinal cancer. Eur J Cancer 1999;35:371-379.
25. Lokich J. Infusional 5-FU for advanced colorectal cancer. J Infus Chemother 1995;5:208-211.
26. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-308.
27. de Gramont A, Bosset JF, Milan C et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808-815.
28. Kohne CH, Schoffski P, Wilke H et al. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 1998;16:418-426.
29. Aranda E, Diaz-Rubio E, Cervantes A et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study. Ann Oncol 1998;9:727-731.
30. Petrelli N, Herrera L, Rustum Y et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987;5:1559-1565.
31. Poon MA, O'Connell MJ, Moertel CG et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407-1418.
32. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282-2292.
33. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097-4106.
34. Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-1412. Erratum in: Lancet 1998;352:1634.
35. Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-1412. Erratum in: Lancet 1998;352:1634.
36. Cunningham D, Pyrhonen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-1418.
37. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000;355:1041-1047. Erratum in: Lancet 2000;355:1372.
38. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000;355:1041-1047. Erratum in: Lancet 2000;355:1372.
39. Diaz-Rubio E, Sastre J, Zaniboni A et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 1998;9:105-108.
40. Machover D, Diaz-Rubio E, de Gramont A et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996;7:95-98.
41. Oxaliplatin (Eloxatin™). Physicians' Desk Reference. Montvale, NJ: Medical Economics Co., Inc, 2003:2999-3003.
42. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
43. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-147.
44. Sastre J, Butts C, Cassidy J et al. Capecitabine-oxaliplatin combination (XELOX), effective 1st line therapy for patients (pts) with metastatic colorectal cancer (MCRC): survival update of an international phase II trial. Ann Oncol 2002;13(suppl 5):80.
45. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903. Erratum in: Arch Surg 1986;121:1045.
46. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903. Erratum in: Arch Surg 1986;121:1045.
47. Klinkenbijl JH, Jeekel J, Sahmoud T et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 1999;230:776-782; discussion 782-784.
48. Ducreux M, Rougier P, Pignon JP et al. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 2002;13:1185-1191.
49. Rothenberg ML, Moore MJ, Cripps MC et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996;7:347-353.
50. Stathopoulos GP, Mavroudis D, Tsavaris N et al. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase 11 study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 2001;12:101-103.
51. Rocha Lima CM, Savarese D, Bruckner H et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2002;20:1182-1191.
52. Berlin JD, Catalano P, Thomas JP et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002;20:3270-3275.
53. Heinemann V, Quietzsch D, Gieseler F et al. A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma. Proc Am Soc Clin Oncol 2003;22:250.
54. Rocha-Lima CMS, Rotche R, Jeffery M et al. A randomized phase 3 study comparing efficacy and safety of gemcitabine (GEM) and Irinotecan (I), to GEM alone in patients (pts) with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy. Proc Am Soc Clin Oncol 2003;22:251.
55. Louvet C, Labianca R, Hammel P et al. Gemcitabine versus GEMOX (gemcitabine oxaliplatin) in nonresectable pancreatic adenocarcinoma: Interim results of the GERCOR/GISCAD intergroup phase III. Proc Am Soc Clin Oncol 2003;22:250
56. Susman E. ASCO: gemcitabine and oxaliplatin combo induces response rates in pancreatic cancer patients. Available at: http://www.docguide.com/dg.nsf/PrintPrint/0915B4600F12D8C785256D3A004C8CC1, accessed 11/20/03.
57. Wang X, Pang L, Feng J. A phase II study of etoposide, doxorubicin, and carboplatin in the treatment of advanced gastric cancer. Am J Clin Oncol 2002;25:71-75.
58. Roth AD, Herrmann R, Morant R et al. Cisplatin, doxorubicin and etoposide (PAV) in advanced gastric carcinoma: the SAKK experience. Swiss Group for Clinical Cancer Research (SAKK). Eur J Cancer 1998;34:2126-2128.
59. Ridwelski K, Gebauer T, Fahlke J et al Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 2001;12:47-51.
60. Louvet C, Andre T, Tigaud JM et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002;20:4543-4548.
61. Sulkes A, Smyth J, Sessa C et al. Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 1994;70:380-383.
62. Mavroudis D, Kourousis C, Androulakis N et al. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial. Am J Clin Oncol 2000;23:341-344.
63. Do-Youn O, Kwon JH, Lee JJ et al. Docetaxel+5-fluorouracil+cisplatin combination chemotherapy as a first-line treatment in inoperable or relapsed gastric cancer. Proc Am Soc Clin Oncol 2003;22:342a.
64. Narahara H, Uedo U, Fujitani K et al. Phase II study of CPT-11 plus docetaxel in patients with metastatic gastric cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG 0101). Proc Am Soc Clin Oncol 2003;22:374a.
65. Moertel CG, Fleming TR, Macdonald JS et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:321-326.
66. Wolmark N, Rockette H, Fisher B et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993;11:1879-1887.
67. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444-1450.
68. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-914.
69. Leichman CG, Fleming TR, Muggia FM et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995;13:1303-1311.
70. Meta-analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998;16:3537-3541.
71. Douillard JY, Hoff PM, Skillings JR et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3605-3616.
72. Carmichael J, Popiela T, Radstone D et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3617-3627.
73. Goldberg RM, Morton RF, Sargent DJ et al. N9741: oxaliplatin (Oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or Oxal + CPT-11 in advanced colorectal cancer (CRC). Updated efficacy and quality of life (QOL) data from an intergroup study. Proc Am Soc Clin Oncol 2003;22:1009a.
74. Tabernero J, Butts CA, Cassidy J et al. Capecitabine and oxaliplatin in combination (Xelox) as first line therapy for patients (pts) with metastatic colorectal cancer (MCRC): results of an international multicenter phase II trial. Proc Am Soc Clin Oncol 2002;21:133a.
75. Scheithauer W, Kornek GV, Raderer M et al. Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer. J Clin Oncol 2002;20:165-172.
76. Bismuth H, Adam R, Levi F et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996;224:509-520; discussion 520-522.
77. Giacchetti S, Itzhaki M, Gruia G et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999;10:663-669.
78. Shih C, Chen VJ, Gossett LS et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-1123.
79. Hanauske AR, Chen V, Paoletti P et al. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. The Oncologist 2001;6:363-373.
80. Rusthoven JJ, Eisenhauer E, Butts C et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999;17:1194.
81. Spielmann M, Martin M, Hamer M et al. Activity of MTA (multitargeted antifolate, LY231514) in metastatic breast cancer (MBC) patients previously treated with an anthracycline and a taxane. Breast Cancer Res Treat 1999;57:123a.
82. John W, Picus J, Blanke CD et al. Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. Cancer 2000;88:1807-1813.
83. Adjei AA, Erlichman C, Sloan JA et al. Phase 1 and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 2000;18:1748-1757.
84. Calvert H. Folate status and the safety profile of antifolates. Semin Oncol 2002;29 (suppl 5):3-7.
85. 12 and folate reduce toxicity of Alimta™ (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite. Proc Am Soc Clin Oncol 2001;20:76a.
86. Miller KD, Picus J, Blanke C et al. Phase II study of the multitargeted antifolate LY231514 (ALIMTATM, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann Oncol 2000;11:101-103.
87. Celio L, Bajetta E, Buzzoni R et al. Efficacy and toxicity of pemetrexed disodium (Alimta) with folic acid (FA) in gastric cancer. Proc Am Soc Clin Oncol 2001;20:166a.
88. Cripps C, Burnell M, Jolivet J et al. Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study. Ann Oncol 1999;10:1175-1179.
89. Kindler HL, Dugan W, Hochster H et al. Clinical outcome in patients (pts) with advanced pancreatic cancer treated with pemetrexed/gemcitabine. Proc Am Soc Clin Oncol 2002;21:125a.
90. Clinical Trials PDQ®. National Cancer Institute. http://cancer.gov/search/clinical_trials.
91. Atkins JN, Jacobs S, Wieand S et al. Pemetrexed and oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the NSABP foundation research program. Proc Am Soc Clin Oncol 2003;22:1108a.
92. Brett BT, Smith SC, Bouvier CV et al. Phase II study of antigastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J Clin Oncol 2002;20:4225-4231.
93. Morse MA. Technology evaluation: CEA-TRICOM, Therion Biologics Corp. Curr Opin Mol Ther 2001;3:407-412.
94. Zonder JA, Shields AF, Zalupski M et al. A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer. Clin Cancer Res 2001;7:38-42.
95. Senderowicz AM. Small molecule modulators of cyclin-dependent kinases for cancer therapy. Oncogene 2000;19:6600-6606.
96. LoRusso PM, Adjei AA, Meyer MB et al. A phase 1 clinical and pharmacokinetic evaluation of the oral MEK inhibitor, CI-1040, administered for 21 consecutive days, repeated every 4 weeks in patients with advanced cancer. Proc Am Soc Clin Oncol 2002;21:81a.
97. Rosenberg AH, Loehrer PJ, Needle MN et al. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr). Proc Am Soc Clin Oncol 2002;21:135a.
98. Saltz L, Rubin M, Hochster H et al. Cetuximab (IMC-225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001;20:3a.
99. Cunningham D, Humblet Y, Siena S et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2003;22:252.
100. Van Laethem JL, Raoul JL, Mitry E et al. Cetuximab (C225) in combination with bi-weekly irinotecan (CPT-11), infusional 5-fluorouracil (5-FU) and folinic acid (FA) in patients (pts) with metastatic colorectal cancer (CRC) expressing the epidermal growth factor receptor (EGFR). Preliminary safety and efficacy results. Proc Am Soc Clin Oncol 2003;22:264.
101. Kris MG, Natale RB, Herbst RS et al. A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL-2). Proc Am Soc Clin Oncol 2002;21:292a.
102. Fukuoka M, Yano S, Giaccone G et al. Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 2002;21:298a.
103. Cho CD, Fischer GA, Halsey J et al. A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with unresectable or metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003;22:265.
104. Yia W, Mullin RJ, Keith BR et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGFR activation of EGFR/erb-B2 pathways. Proc Am Soc Clin Oncol 2002;21:94a.
105. Belanger M, Jones CM, Germond C et al. A phase II, open-label, multicenter study of GW572016 in patients with metastatic colorectal cancer refractory to 5-FU5-FU in combination with irinotecan and/or oxaliplatin. Proc Am Soc Clin Oncol 2003;22:244a.
106. Garrison MA, Tolcher A, McGreery H et al. A phase I pharmacokinetic study of CI-1033, a pan-erb-B tyrosine kinase inhibitor, given orally on days 1, 8, and 15 every 28 days to patients with solid tumors. Proc Am Soc Clin Oncol 2002;21:72a.
107. Rowinski EK, Garrison M, Lorusso P et al. Administration of CI-1033, an irreversible pan erb-B tyrosine kinase (TK) inhibitor is feasible on a 7-day on/7-day off schedule: a phase I, pharmacokinetic (PK), and food effect study. Proc Am Soc Clin Oncol 2003;22:201a.
108. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65,
109. Hurwitz H, Fehrenbacher L, Cartwright T et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc Am Soc Clin Oncol 2003;22. Available at: http://www.asco.org/hurwitz_no3646.
110. Thomas AL, Morgan B, Drevs J et al. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin Oncol 2003;30(suppl 6):32-38.
111. Steward WP, Thomas AL, Morgan B et al, Extended phase I study of the oral vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK 222584 in combination with oxaliplatin/5-fluorouracil (5-FU)/leucovorin as first line treatment for metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003;22:274a.
112. Venook A, Hurwitz H, Cunningham C et al. Relationship of clinical outcome in metastatic colorectal carcinoma to levels of soluble VEGFR-1: results of a phase II trial of a ribozyme targeting the pre-mRNA of VEGFR-1 (angiozyme), in combination with chemotherapy. Proc Am Soc Clin Oncol 2003;22:256a.
113. Ciardiello F, Bianco R, Caputo R et al. Antitumor activity of ZD6474, a small molecule VEGF receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to EGF receptor-targeted drugs. Proc Am Soc Clin Oncol 2003;22:205a.
114. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-266.
115. Ornstein DL, Zacharski LR. The use of heparin for treating human malignancies. Haemostasis 1999;29(suppl S1):48-60.
116. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002;8(suppl):S55-S61.